Abstract
Scott et al. conducted a systematic review to evaluate the risk of myocardial infarction (MI) associated with cyclo-oxygenase-2 (COX2) inhibitors and traditional NSAIDs. The review found a small increased risk of MI associated with COX2 inhibitors, particularly rofecoxib. Although a fixed-effects model of 14 case–control studies suggested a slightly increased risk of MI with NSAID use, a random-effects model of the same data and analysis of 6 cohort studies found no such link. An increased risk of MI was found in four RCTs of NSAID use in colonic adenoma. In an analysis of 14 RCTs that compared COX2 inhibitors with traditional NSAIDs in patients with arthritis, the odds ratio for MI with COX2 inhibitors was 1.6 (95% CI 1.1–2.4), although most of this risk was accounted for by rofecoxib. COX2 inhibitors were, however, associated with a reduced risk of serious gastrointestinal events. An analysis of previous systematic reviews showed increased risks of MI associated with rofecoxib and celecoxib.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kearney PM et al. (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332: 1302–1308
McGettigan P and Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296: 1633–1644
Singh G et al. (2006) Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther 8: R153
Catella-Lawson F et al. (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345: 1809–1817
MacDonald TM and Wei L (2003) Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361: 573–574
Acknowledgements
The summary was written by Jim Casey, Editorial Assistant, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
SB Abramson is a consultant for Novartis, Pfizer, GlaxoSmithKline, Abbott Laboratories, Amgen and Centocor. He has received departmental support from Abbott Laboratories, Bristol-Myers Squibb and Merck, and has investments in Amgen, Bristol-Myers Squibb, Merck, Pfizer and Resolvyx Pharmaceuticals. J Greenberg is a consultant for Novartis and Roche, and has received research support from Bristol-Myers Squibb.
Rights and permissions
About this article
Cite this article
Abramson, S., Greenberg, J. Are NSAIDs and selective cyclo-oxygenase 2 inhibitors associated with increased risk of myocardial infarction?. Nat Rev Rheumatol 4, 182–183 (2008). https://doi.org/10.1038/ncprheum0763
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0763
This article is cited by
-
Synthesis and pharmacological evaluation of some novel 2-pyrazolines bearing benzenesulfonamide as anti-inflammatory and blood glucose lowering agents
Medicinal Chemistry Research (2013)
-
Structure-based molecular design, synthesis, and in vivo anti-inflammatory activity of pyridazinone derivatives as nonclassic COX-2 inhibitors
Medicinal Chemistry Research (2010)
